News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “China Proton Therapy Outlook 2020”, significant investment by major players in the proton therapy market will aid in a significant increase in the Chinese Proton therapy Market.
 
Of various types of cancer treatment, proton therapy has witnessed major foreign investment in China. For instance, in December 2014, IBA (Ion Beam Applications), the market leader  of proton therapy solutions for the treatment of cancer entered into an initial US$ 34.3 Million agreement with Guangdong Hengju Medical Technologies,  to install the first proton therapy system in South China. It further followed with a US$ 22 Million extension to its collaboration agreement for two additional gantry treatment rooms.
 
Moreover, in October 2015, Sinophi Healthcare, a UK based firm that manages hospitals in China has signed an exclusive deal to open proton therapy in seven hospitals in China worth US$ 12.3 Billion. The seven hospitals include one oncology hospital with a proton center and one maternity hospital in the city of Huai’an, as well as five Sinophi Proton Centers in Beijing, Changchun, Fuzhou, Luoyang and Nanjing. It is expected that these Sinophi Proton Centers in China will bring together the best of Chinese oncology treatment and expertise with the advanced proton therapy technology of Advanced Oncotherapy plc.
 
In another significant development, in May 2015, Concord Medical Services Holdings (the operator of the largest network of radiotherapy and diagnostic imaging centers in China) signed a multi-year strategic development agreement with the University of Texas MD Anderson Cancer Center. This strategic deal would serve as an exclusive collaboration at Concord Medical’s new cancer facilities in Shanghai and Beijing, and the collaboration exclusivity will cover most of the provinces in China, and in Singapore.
 
In addition, Advanced Oncotherapy, developer of next-generation proton therapy systems for cancer treatment, confirmed that, Sinophi Healthcare, its Chinese partner, had signed an agreement with China-Japan Union Hospital of Jilin University in north east China in relation to a proton therapy center. With such investments in the country, the Proton Therapy market is all set to soar high in China.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM790.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm